- Chemical formula – C28H27NO4S
- Weight – 473.6
Discovery of Ralox:
Raloxifene or Ralox is a drug which is indicated for the prevention and treatment of osteoporosis disease in women suffering from the cessation of menstruation (menopause) or are on intake of glucocorticoids. In the initial phases, raloxifene was approved for medical intervention in the United States in the year 1997. Raloxifene is recently available as a specific generic medicine because it was the most prescribed drug exceeding about 9-lac prescriptions annually.
Mechanism of action of Raloxifene:
Raloxifene is the selective estrogen receptor modulator which acts as an antagonist to the estrogen and as the estrogen-specific estrogen receptor agonist. Based on different findings, Raloxifene tends to have a higher affinity of binding like the action of estradiol.
In the human body, estrogens play a significant role in the development and working of different body tissues. In mechanism, Raloxifene mimics the working of natural/endogenous estrogen present in the tissues of bone. As the most common treatment, Raloxifene helps in the prevention and treatment of corticosteroid-induced bone loss and osteoporosis in women (post-menopausal). Furthermore, Raloxifene is also helpful in reducing the risk of malignant and invasive cancer due to osteoporosis in women during menopause.
Raloxifene clinical applications:
Prevention and treatment of osteoporosis:
Raloxifene is the selective estrogen receptor modulator (SERM), which interacts with the body’s oestrogen receptors to function as an antagonist and agonist in tissues simultaneously. Due to Raloxifene’s unique properties, the required benefits can be achieved without affecting breast and uterus tissues. In osteoporosis, females suffer from hormonal deficiencies, which normally need hormonal therapies as interventions. Raloxifene is an alternative treatment in comparison to conventional therapies for osteoporosis prevention and treatment.
Prevention of breast cancer:
Breast cancers are of two types – invasive and non-invasive. Invasive cancer of the breast is malignant and spreads rapidly to the tissues of the surrounding areas as lobules and milk ducts. The most dangerous type of breast cancer is invasive breast cancer which needs a different treatment regimen.
In the medical field, another exceptional indication of Raloxifene is the treatment and early prevention of invasive breast cancer among women. The mechanism of action behind the working of Raloxifene is the blockage of estrogen receptors in the tissues of breasts. Due to this property, Raloxifene decreases the amount of estrogen hormone, which is required for the proliferation of hormone-induced cancer. As per the clinical evidence, this drug is the most appropriate choice for the prevention and treatment of invasive breast cancer in women (post-menopausal).
The data provided in this article about Raloxifene has been written to provide knowledge for the research purposes only. The article is specifically designed to provide information about Raloxifene rather than giving instructions about the use of it. Furthermore, there has been no mention of the route of administration or dosage of the Ralox. The information provided in the article has been collected from different published researchers by a group of expert researchers keeping the medical protocols in view.
Furthermore, this article does not contain any information to encourage readers to consume or advertise Ralox. We do not condone any advertisement of any supplement or drug that the FDA has not approved. Melanotan Express insists that no product should be ingested under any circumstances.
- Raloxifene | Compound| Pubchem| Link: https://pubchem.ncbi.nlm.nih.gov/compound/Raloxifene
- Raloxifene | Compound|Chemspider| Link: http://www.chemspider.com/Chemical-Structure.4859.html
- Waters, E. A., McNeel, T. S., Stevens, W. M., & Freedman, A. N. (2012). Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast cancer research and treatment, 134(2), 875-880.
- O’Regan, R. M., Osipo, C., Ariazi, E., Lee, E. S., Meeke, K., Morris, C., … & Jordan, V. C. (2006). Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. Clinical cancer research, 12(7), 2255-2263.
- Vogel, V. G., Costantino, J. P., Wickerham, D. L., Cronin, W. M., Cecchini, R. S., Atkins, J. N., … & National Surgical Adjuvant Breast and Bowel Project. (2006). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. Jama, 295(23), 2727-2741.
- Snyder, K. R., Sparano, N., & Malinowski, J. M. (2000). Raloxifene hydrochloride. American Journal of Health-System Pharmacy, 57(18), 1669-1675.
Where to find Raloxifene for Sale?
If you are looking to buy Raloxifene for research purposes, visit Melanotan Express, one of the leading suppliers of the USA Peptides and SARMs for sale: https://www.melanotanexpress.com/product/ralox-50mg-per-ml-30ml-bottle/